Global Biopharmaceuticals Market - 2019-2026
発行: DataM Intelligence
The global Biopharmaceuticals market was valued at USD xx million in 2016, USD xx million in 2017, and is estimated to reach USD xx million by 2025, with a CAGR of xx% during the forecast period (2018-2025).
Biopharmaceuticals are medicinal drugs which helps in prevention and treatment of various diseases such as cardiovascular disease, rheumatoid arthritis, psoriatic arthritis, psoriasis, anemia arising from chemotherapy, chronic renal failure, cancer, and diabetes.
The market is driven by several factors such as ability of biopharmaceuticals to treat previously untreatable diseases, increased uptake of biopharmaceuticals, huge market demand, and growing aging population. But the market is affected by the challenging development process, and stringent regulatory framework.
The global Biopharmaceuticals market is segmented by product type such as Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Synthetic Immunomodulators, Vaccines & Recombinant Enzymes, and Others. Among these, Monoclonal antibodies are the fastest growing segment. Some of the top-selling monoclonal antibodies include Adalimumab, Infliximab, Rituximab and Bevacizumab.
Based on applications, the global biopharmaceuticals market can be segmented into oncology, inflammatory and infectious diseases, autoimmune disorders, metabolic disorders, hormonal disorders, disease prevention, cardiovascular diseases, neurological diseases and other diseases. Oncology is the largest segment in the biopharmaceuticals market as biopharmaceuticals have wide applications in the pharmaceutical industry.
Geographically, the market is segmented into North America, South America, Europe, Asia Pacific and RoW. North America is the largest market for biopharmaceuticals due to technological advancements in the region. The North America market for biopharmaceuticals was valued at US$ 64.7 Bn in 2014 and is expected to reach grow at a CAGR of 9.5% over the forecast period.
The graph represents the worldwide biopharmaceutical-related venture capital investments in 2010. In that year, the venture capital investments in this sector amounted to 8.23 billion U.S. dollars in the United States. The worldwide venture capital investments amounted to 12.48 billion U.S. dollars.
The major companies in the Biopharmaceuticals market includes Abbvie Inc., Amgen, Bayer, Biogen, Bristol-Myers Squibb, ELI Lilly and Company, Johnson and Johnson, Merck & Co. Inc., Novartis AG, Novo Nordisk, Pfizer, Glaxosmithkline PLC, Sanofi S.A, and Takeda Pharmaceutical.
In Sept 2017, Arizona-based company HSRx Biopharmaceutical announced that its orally administered broad-spectrum antiviral drug HSRx 431™ is effective against the Zika virus. They plan to test their claim by conducting human trials in 2017, and if these are found to be successful, they plan to seek accelerated drug approval from the U.S. FDA.
There are several challenges faced in pharmaceuticals market. One of the challenge is the requirement of cold storage for almost all the biopharmaceuticals. This limits their reach in the developing and third world countries. The process of developing a biopharmaceutical is also extremely difficult, as it involves living biological systems which limits the scalability, as scaling a biological system is different from scaling an equipment-based system.
The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.
\4.2.7. Cardiovascular Diseases